GlassScriptPhysician profile
Jed D Gould
NPI 1629067350
$3,115.17
in general payments reported to CMS, 2019-2025
24 companies · $18.37 in 2025
The $18.37 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $234 · 2021: $1,015 · 2022: $682 · 2023: $269 · 2024: $151 · 2025: $18.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,047.45 | 2019-2023 | |
| Aspira Women'S Health INC | $332.60 | 2021-2022 | |
| Renovia INC | $242.57 | 2019-2021 | |
| Exeltis, USA INC. | $225.80 | 2019-2023 | Slynd |
| Pfizer INC. | $155.80 | 2019-2023 | |
| Coopersurgical, INC. | $145.14 | 2019-2023 | Paragard T 380a, Summit Doppler |
| Amgen INC. | $135.76 | 2019-2022 | |
| Astellas Pharma US INC | $127.63 | 2022-2024 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $125.27 | 2019-2022 | |
| Daiichi Sankyo INC. | $92.36 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $74.39 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $72.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $54.76 | 2019-2023 | Gardasil 9 |
| Myovant Sciences INC. | $46.93 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $41.56 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $33.85 | 2019-2025 | Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $27.64 | 2022 | |
| Mylan Pharmaceuticals INC. | $26.62 | 2021 | |
| Roche Diagnostics Corporation | $24.38 | 2019 | |
| Glaxosmithkline, LLC. | $20.68 | 2022 | |
| Scynexis, INC. | $19.83 | 2022 | |
| Axonics, INC. | $17.75 | 2023 | Axonics |
| Vertical Pharmaceuticals, LLC | $12.42 | 2019 | |
| Evofem Biosciences, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jed Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.